Sarcoma
The U.S. Food and Drug Administration has granted orphan drug designation status to a novel, humanized monoclonal antibody APX005M (Apexigen) for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer.
“These orphan drug designations are important regulatory milestones for Apexigen in its mission to treat cancer patients and for APX005M, which has the potential to…
featured stories
View Conference Coverage
Take a look at some of our conference coverage, visit our roundup section.
Videos
-
May 19, 2020
ASCO - Retroperitoneal Sarcomas: the Benefits of…
-
May 19, 2020
Genetic Landscape of Soft-tissue Sarcomas
-
May 19, 2020
2019 ASCO Annual Meeting Research Round Up: Soft-…
Conference Roundup
- Jul 26, 2020
Pooled data shows tazemetostat safe, effective in patients with epithelioid sarcoma
Tazemetostat provides clinically meaningful, durable, single agent activity in patients with epithelioid sarcoma, according to data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program…
Journal Scan
- Oct 13, 2020
Case Report: Sarcoma with metastatic pulmonary dissemination mimics COVID-19 clinical features
In this case report, a 13-year-old boy with fever, dry cough, persistent asthenia and impaired general condition of 2 weeks' duration, presented to the hospital. Bloodwork showed a severe inflammatory status and X-rays were consistent with bilateral COVID-19…
Trending Topics
- Oct 20, 2020
FDA grants orphan drug designation to APX005M for rare cancers
The U.S. Food and Drug Administration has granted orphan drug designation status to a novel, humanized monoclonal antibody APX005M (Apexigen) for the treatment of esophageal and gastroesophageal junction…
